Jpmorgan Chase & CO Relmada Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 352,616 shares of RLMD stock, worth $1.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

352,616

Previous 175,978 100.38%

Holding current value

$1.21 Million

Previous $818,000 29.22%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$2.93 - $4.94 $517,549 - $872,591	176,638 Added 100.38%	352,616 $1.06 Million
Q1 2024 May 10, 2024	BUY	$3.1 - $6.8 $487,264 - $1.07 Million	157,182 Added 836.25%	175,978 $818,000
Q4 2023 Feb 12, 2024	BUY	$2.45 - $4.22 $43,945 - $75,694	17,937 Added 2088.13%	18,796 $77,000
Q2 2023 Aug 11, 2023	SELL	$2.22 - $3.54 $44,670 - $71,231	-20,122 Reduced 95.91%	859 $2,000
Q1 2023 May 18, 2023	BUY	$2.24 - $4.76 $46,997 - $99,869	20,981 New	20,981 $47,000
Q4 2022 Feb 13, 2023	SELL	$2.17 - $35.84 $3,448 - $56,949	-1,589 Reduced 9.3%	15,503 $54,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $20,422 - $41,314	1,116 Added 6.99%	17,092 $633,000
Q2 2022 Aug 11, 2022	BUY	$16.5 - $30.34 $2,079 - $3,822	126 Added 0.79%	15,976 $304,000
Q1 2022 May 11, 2022	BUY	$16.72 - $26.99 $140,882 - $227,417	8,426 Added 113.5%	15,850 $427,000
Q4 2021 Feb 10, 2022	SELL	$16.93 - $26.82 $56,918 - $90,168	-3,362 Reduced 31.17%	7,424 $167,000
Q3 2021 Nov 12, 2021	BUY	$21.86 - $34.77 $235,781 - $375,029	10,786 New	10,786 $283,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

13.5M

Call Options Held

99K

Put Options Held

28.2K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $97.8M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Relmada Therapeutics, Inc. Transaction History